About this trial
The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV).
The main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment? Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.
Eligibility criteria
Qualifiers
Recent history of miscarriage or delivery (within the past 8 weeks)
Strong willingness to undergo conservative management
Hemodynamically stable
Signed informed consent form
Disqualifiers
Heavy vaginal bleeding (requiring immediate surgical intervention)
Active pelvic or systemic infection (e.g., fever >38°C, elevated CRP/WBC)
Severe dysfunction of vital organs (heart, liver, or kidney)
Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)
Trial design
Treatments tested in this trial
- Not listed